Docro to Help ArrayIt with FDA Process for OvaDx | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – ArrayIt today said that it has signed an agreement with Docro to assist in its efforts to win US Food and Drug Administration clearance for its OvaDx test.

ArrayIt's OvaDx is a pre-symptomatic ovarian cancer test that includes 100 proteomic biomarkers in a microarray format. The Sunnyvale, Calif.-based firm said that the test can detect both early- and late-stage ovarian cancer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: chromosome instability in S. cerevisiae, structural differences and sequence divergence in rice, and more.

The San Diego Union-Tribune takes a look at the work to be done in personalized medicine.

An op-ed in the Wall Street Journal calls for the establishment of a patent court staffed by judges and experts with science backgrounds.

In PLOS this week: variants that affect COPD biomarkers, high genetic diversity of Cryptococcus gattii in Brazil, and more.